Delivery Order SPE2DB22D1017-SPE2DB25FYPAK
Award Date 8/25/25
Potential Completion Date 8/26/25
Potential Value $15K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $18,491.04 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is a non-set-aside procurement with an ultimate completion date of August 18, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $4,724.63 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used to treat rheumatoid arthritis...
- The Defense Logistics Agency awarded a delivery order valued at $12.3K to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 13, 2025, with completion targeted for August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for RINVOQ ER 15 MG tablets in a quantity of 30 units, with a ceiling value of $26,170.68. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is expected to be completed by August 14, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $10,006.04 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with completion expected by July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.86 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $35,073.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 30, 2025, with performance completion due July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026 that provides comprehensive pharmaceutical and...
- The Defense Logistics Agency awarded a $29,485.37 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a $5,099.34 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 25, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, making this...